These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22266917)

  • 1. Synthesis, pharmacokinetics, and pharmacodynamics studies of valsartan peptide derivatives.
    Wu C; Hu Y; Li Q; He L; Chen J; Cheng Z; Li Y; Hu G
    Arch Pharm (Weinheim); 2012 May; 345(5):393-400. PubMed ID: 22266917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM; Hilkert R
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
    Deeks ED
    Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
    Kondrack R; Mohiuddin S
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan.
    Daneshtalab N; Lewanczuk RZ; Russell A; Jamali F
    J Clin Pharmacol; 2004 Mar; 44(3):245-52. PubMed ID: 14973301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of valsartan via decarboxylative biaryl coupling.
    Goossen LJ; Melzer B
    J Org Chem; 2007 Sep; 72(19):7473-6. PubMed ID: 17715979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
    Ismail MA; Barker S; Abou el-Ella DA; Abouzid KA; Toubar RA; Todd MH
    J Med Chem; 2006 Mar; 49(5):1526-35. PubMed ID: 16509571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats.
    Huo X; Liu Q; Wang C; Meng Q; Sun H; Peng J; Ma X; Sun P; Liu K
    J Pharm Sci; 2014 Feb; 103(2):719-29. PubMed ID: 24338900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
    El-Gamal MI; Anbar HS; Chung HJ; Kim HI; Cho YJ; Lee BS; Lee SA; Moon JY; Lee DJ; Kwon D; Choi WJ; Jeon HR; Oh CH
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1347-50. PubMed ID: 23347686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models.
    Challa VR; Babu PR; Challa SR; Johnson B; Maheswari C
    Drug Dev Ind Pharm; 2013 Jun; 39(6):865-72. PubMed ID: 22670860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.
    Park YJ; Lee HK; Im YB; Lee W; Han HK
    Arch Pharm Res; 2010 Aug; 33(8):1235-40. PubMed ID: 20803127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
    Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
    Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
    Li DX; Yan YD; Oh DH; Yang KY; Seo YG; Kim JO; Kim YI; Yong CS; Choi HG
    Drug Deliv; 2010 Jul; 17(5):322-9. PubMed ID: 20367177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.